Jack Dent (@jackdent) / X

Jack Dent

126 posts

Jack Dent

@jackdent

Co-Founder @chaidiscovery

Joined May 2011

Jack Dent
@jackdent
Jul 28
Huge thanks to @Sachin_and_Adam for visiting Chai HQ! Loved hosting you both and demoing what our tech can do. Watch the full video here 👇
Sachin and Adam
@Sachin_and_Adam
Jul 28
Exclusive: Inside $3.8B @chaidiscovery After leaving OpenAI & Stripe, co-founders Josh Meier (@joshim5) and Jack Dent (@jackdent) built a pioneering AI drug design model called Chai-1. Now? Their models are used by giants like Eli Lilly, Pfizer and Novartis. Their models
00:00
Jack Dent
@jackdent
Jul 28
Conviction was there from the start for Chai
Bella
@igarciacamargo
Jul 28
applications for Embed now open, due 8/10 Embed is a Schelling Point for the best early stage founders. cash, compute, community, & a catalyst past participants were dropouts, leading researchers and repeat founders alumni have raised more than a billion dollars links in🧵
Jack Dent
@jackdent
Jul 15
What a week at @chaidiscovery. In the last 3 days: - Unveiled our collaboration with @Novartis - Announced our $400M Series C - A new agreement with @argenxglobal
Chai Discovery
@chaidiscovery
Jul 15
We’re delighted to announce our third agreement this week, this time a collaboration with @argenxglobal. argenx has built one of biotechnology’s most productive antibody engines. We’ll be putting Chai’s frontier molecular design platform into the hands of their scientists.
00:00
Jack Dent
@jackdent
Jul 15
Thank you @tbpn for having me on to talk about the breathtaking pace of model development in AI<>bio, just how large the pharma industry is (sneak peek: even bigger than the chip industry, by revenue), and our Series C.
TBPN
@tbpn
Jul 14
Chai Discovery cofounder @jackdent says AI drug discovery hit a major inflection point in 2025. As a result, it's now being deployed at the biggest pharma companies as part of their core discovery engines. "Over the course of 2025, these models went from being research
00:00
Jack Dent
@jackdent
Jul 14
Thrilled to announce our $400M Series C led by @IndexVentures, with @kleinerperkins, @sequoia, @_DimensionCap and others. Great to speak to @m_delamerced @nytimes about how drug discovery using AI is moving from a promise to actual deployment.